|
THE SIMPLE FACTSTM...Gadolinium is an FDA-approved contrast agent for magnetic resonance imaging (MRI). Gadolinium is also called gadolinium-DPTA and gadodiamide, and it goes by various brand names. Gadolinium is non-radioactive and resembles plain water.
FDA REPORTS
FDA reports have identified a possible link between Nephrogenic Systemic Fibrosis (NSF) and/or Nephrogenic Fibrosing Dermopathy (NFD) and exposure to gadolinium containing contrast agents used at high doses for a procedure called Magnetic Resonance Angiography (MRA).
In particular, the FDA black box warning - updated on 5/23/2007 - reports that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, and a potentially fatal disease known as nephrogenic systemic fibrosis (NSF). Five gadolinium-based MRI contrast agents have been approved for use in the United States:
• Magnevist (gadopentetate dimeglumine)
• Ominiscan (gadodiamide)
• OptiMARK (gadoversetamide)
• MultiHance (gadobenate dimeglumine)
• Prohance (gadoteridol)
In addition, the FDA released an informational video on gadolinium based contrast agents. To view the FDA video, click here - FDA Video: New Warnings for MRI Contrast Agents Containing Gadolinium.
For more information on Gadolinium as a contrast agent for MRI/MRA and the possible injuries - Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy from using Gadolinium as a contrast agent, click here.
In addition, an MDL has been setup in the Northern District of Ohio, Eastern Division for Gadolinium-based contrast agent litigation (IN RE: Gadolinium-based Contrast Agents Products Liability Litigation No. 1909).
Quite frankly, the simple factsTM about the use of Gadolinium as a contrast agent for MRI/MRA and the possible injuries - Nephrogenic Systemic Fibrosis (NSF) and Nephrogenic Fibrosing Dermopathy from using Gadolinium as a contrast agent are unacceptable.
We are currently investigating cases involving gadolinium-containing contrast agents used in patients with kidney failure and a disease known as Nephrogenic Systemic Fibrosis (NSF) and/or Nephrogenic Fibrosing Dermopathy (NFD).
We are here to help you protect your legal rights and the legal rights of your loved ones.
|
